Kirik D - Search Results

1

Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.

Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D. Eslamboli A, et al. Among authors: kirik d. Brain. 2007 Mar;130(Pt 3):799-815. doi: 10.1093/brain/awl382. Epub 2007 Feb 15. Brain. 2007. PMID: 17303591

2

Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).

Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Kirik D, Annett LE. Eslamboli A, et al. Among authors: kirik d. Exp Neurol. 2003 Nov;184(1):536-48. doi: 10.1016/j.expneurol.2003.08.007. Exp Neurol. 2003. PMID: 14637123

3

Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D. Eslamboli A, et al. Among authors: kirik d. J Neurosci. 2005 Jan 26;25(4):769-77. doi: 10.1523/JNEUROSCI.4421-04.2005. J Neurosci. 2005. PMID: 15673656 Free PMC article.

4

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A. Kirik D, et al. J Neurosci. 2002 Apr 1;22(7):2780-91. doi: 10.1523/JNEUROSCI.22-07-02780.2002. J Neurosci. 2002. PMID: 11923443 Free PMC article.

5

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.

Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A. Kirik D, et al. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2884-9. doi: 10.1073/pnas.0536383100. Epub 2003 Feb 24. Proc Natl Acad Sci U S A. 2003. PMID: 12601150 Free PMC article.

6

Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.

Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, Björklund A, Kirik D. Carlsson T, et al. Among authors: kirik d. Brain. 2005 Mar;128(Pt 3):559-69. doi: 10.1093/brain/awh374. Epub 2005 Jan 19. Brain. 2005. PMID: 15659429

7

Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease.

Maingay M, Romero-Ramos M, Kirik D. Maingay M, et al. Among authors: kirik d. CNS Spectr. 2005 Mar;10(3):235-44. doi: 10.1017/s1092852900010075. CNS Spectr. 2005. PMID: 15744224 Review.

8

Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.

Maingay M, Romero-Ramos M, Carta M, Kirik D. Maingay M, et al. Among authors: kirik d. Neurobiol Dis. 2006 Sep;23(3):522-32. doi: 10.1016/j.nbd.2006.04.007. Epub 2006 Jun 30. Neurobiol Dis. 2006. PMID: 16806952

9

In vivo gene delivery for development of mammalian models for Parkinson's disease.

Ulusoy A, Bjorklund T, Hermening S, Kirik D. Ulusoy A, et al. Among authors: kirik d. Exp Neurol. 2008 Jan;209(1):89-100. doi: 10.1016/j.expneurol.2007.09.011. Epub 2007 Sep 22. Exp Neurol. 2008. PMID: 18028909 Review.

10

Scientific rationale for the development of gene therapy strategies for Parkinson's disease.

Björklund T, Kirik D. Björklund T, et al. Among authors: kirik d. Biochim Biophys Acta. 2009 Jul;1792(7):703-13. doi: 10.1016/j.bbadis.2009.02.009. Epub 2009 Feb 27. Biochim Biophys Acta. 2009. PMID: 19254760 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters